PURPOSEThe development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with …
In 2025, ASCO published a guideline update on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer (stages I and…
Resection of liver metastases is considered the only treatment with curative potential for patients with metastatic colorectal cancer to the liver (CRLM). However, only a…
PURPOSETo assess the impact and outcomes of a novel program for routine preemptive DPYD testing in fluoropyrimidine (FP)-naïve patients.PATIENTS AND METHODSThis single-center, retrospective cohort study…
PURPOSEThe development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy…
Twitter use has increased among patients with cancer, advocates, and oncology professionals. Hashtags, a form of metadata, can be used to share content, organize health…
PURPOSEAdjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC). Neoadjuvant treatment could improve…
This clinical insights article is derived from recommendations in SLNB in Early-Stage Breast Cancer: ASCO Guideline Update. This document is based on an ASCO Guideline…
PURPOSEImproved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have <50% chance of cure with first-line (1L) R-CHOP chemotherapy. Patients…
PURPOSEImproved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have <50% chance of cure with first-line (1L) R-CHOP chemotherapy. Patients…
